Rabicon / Rabicon-L
Rabeprazole Sodium 20 mg (± Levosulpiride 75 mg SR)
Clinical Differentiators & Advantages
PCD Franchise Distribution
Verify if exclusive marketing and distribution rights for Rabicon / Rabicon-L are currently vacant in your target district.
Active Chemical Compounds & Molecular Architecture
Validated chemical entities, 2D skeletal bond diagrams, empirical molecular formulas, and receptor-level modes of action
Fastest-acting proton pump inhibitor achieving superior endoscopic mucosal healing rates.
Advanced prokinetic acting on both proximal and distal bowel, unlike domperidone.
Approved Clinical Indications & Disease Burden
Pharmacodynamic Mechanism of Action
Fastest pKa proton pump inhibition: Rabeprazole is converted into active sulfenamide at higher pH than other PPIs, initiating faster acid shutdown. Levosulpiride selectively blocks central and peripheral dopamine D2 receptors while enhancing 5-HT4 mediated acetylcholine release, restoring coordinated peristalsis along BOTH the proximal AND distal gut.
Dosage & Administration Protocol
1 capsule daily in the morning on an empty stomach, 30 minutes before food.
Precautions, Warnings & Contraindications
B2B Commercial & Shipping Metrics
Moisture-sealed 5-ply export corrugation
Includes visual aids & promotional inputs
Private label & institutional supply
Standard pharmaceutical commercial tariff
Certificate of Analysis (COA), Stability Study Reports (Zone IVb), Finished Product Specs (FPS), and Material Safety Data Sheet (MSDS).
Frequently Prescribed & Stocked Together
Clinically aligned formulations commonly co-prescribed with Rabicon / Rabicon-L to improve patient outcomes and expand distributor portfolio basket size.
Pandom / Pandom-SR
Pantoprazole 40 mg + Domperidone 10 mg / 30 mg SR
“Controls Acid & Reflux — The GI Fire Extinguisher”